What is the appropriate management for Profex Super (profenofos and cypermethrin) poisoning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Profex Super (Profenofos and Cypermethrin) Poisoning

Immediately administer atropine for severe symptoms, perform thorough dermal decontamination with personal protective equipment, consider pralidoxime for the organophosphate component, and provide aggressive supportive care including early intubation if needed.

Understanding the Toxidrome

Profex Super contains two distinct pesticides requiring a dual management approach:

  • Profenofos (organophosphate): Inhibits acetylcholinesterase causing cholinergic crisis
  • Cypermethrin (pyrethroid): Delays sodium channel closure causing neurotoxicity

The clinical presentation may be atypical and delayed. Profenofos can cause status epilepticus up to 36 hours post-ingestion without peripheral cholinergic signs due to its high lipophilicity and preferential CNS accumulation 1. Cypermethrin can mimic organophosphate poisoning with bradycardia and cholinergic-like features 2, 3.

Immediate Management Algorithm

1. Decontamination (Class I Recommendation)

  • Remove all contaminated clothing immediately
  • Copious soap and water irrigation of skin
  • Healthcare workers MUST wear appropriate personal protective equipment to prevent secondary contamination 4
  • This is critical as both compounds have dermal absorption

2. Atropine Administration (Class I, Level A)

Indications for immediate atropine 4:

  • Bronchospasm or bronchorrhea
  • Significant bradycardia
  • Seizures
  • Hypotension

Dosing strategy 4:

  • Start with initial dose
  • Double the dose every 5 minutes until full atropinization achieved
  • Target endpoints: clear chest on auscultation, heart rate >80/min, systolic BP >80 mmHg
  • Maintain with continuous atropine infusion
  • Doses required are much higher than typical bradycardia treatment

Important caveat: For cypermethrin component, use low-dose atropine only if symptomatic 2. High-dose atropine may cause complications in pure pyrethroid poisoning, but given the organophosphate component in Profex Super, standard organophosphate dosing is appropriate.

3. Pralidoxime (Oximes) - Class IIa, Level A

Administer pralidoxime early for the profenofos component 4:

  • Most effective when given before "aging" occurs (covalent bonding of organophosphate to acetylcholinesterase)
  • Reverses nicotinic effects: improves respiratory and skeletal muscle strength
  • Should NOT be withheld even though cypermethrin is present—the organophosphate component requires it

4. Airway Management (Class I, Level B-NR)

Early endotracheal intubation is recommended for life-threatening poisoning 4:

  • Observational data show better outcomes with early intubation in significant organophosphate poisoning
  • Consider proactively given risk of delayed seizures and respiratory failure
  • Avoid succinylcholine and mivacurium (Class III recommendation)—these neuromuscular blockers are metabolized by cholinesterase and are contraindicated 4

5. Seizure Management (Class I, Level C-LD)

Benzodiazepines are first-line 4:

  • Diazepam is preferred over midazolam
  • Treat both active seizures and agitation
  • Be vigilant for delayed-onset status epilepticus (up to 36 hours post-ingestion with profenofos) 1
  • Consider continuous EEG monitoring if available
  • May require midazolam infusion for refractory status epilepticus

Special Considerations for Profex Super

Toxicokinetic Factors

  • Ethanol co-ingestion (common in self-poisoning) prolongs profenofos elimination half-life (23.1h vs 9.9h) but doesn't significantly worsen outcomes 5
  • Profenofos has high lipophilicity enabling CNS accumulation and delayed neurotoxicity 1

Monitoring Requirements

  • Continuous cardiac monitoring for bradycardia (cypermethrin effect) 3
  • Serial neurological assessments for delayed seizures
  • Respiratory status (both compounds cause respiratory compromise)
  • Consider continuous EEG if seizures develop

Duration of Observation

  • Minimum 48-72 hours given risk of delayed seizures with profenofos 1
  • Longer if symptomatic or severe ingestion

Common Pitfalls to Avoid

  1. Underestimating atropine requirements: Organophosphate poisoning requires massive doses—don't stop at typical bradycardia doses
  2. Delaying pralidoxime: Effectiveness decreases after "aging" occurs
  3. Premature discharge: Delayed neurotoxicity can occur up to 36 hours post-ingestion
  4. Using contraindicated paralytics: Avoid succinylcholine/mivacurium for intubation
  5. Assuming typical cholinergic presentation: Profenofos may present with isolated CNS toxicity without peripheral signs 1
  6. Overdosing atropine for pure pyrethroid toxicity: While not the primary concern here given the combination product, be aware that isolated cypermethrin poisoning requires only low-dose atropine if symptomatic 2

Supportive Care

  • Mechanical ventilation as needed
  • Hemodynamic support
  • Aspiration precautions (increased secretions, altered mental status)
  • Consider activated charcoal if presenting within 1-2 hours of ingestion (though dermal exposure is primary route)

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.